New therapeutic targets for antiphospholipid syndrome

Abstract

In this issue of Blood, Yamaguchi and colleagues demonstrated the essential role of the β2-glycoprotein I (β2GPI)/phosphatidylserine complex opsonized by IgG anti-β2GPI antibodies in the proliferation of CD4+ T cells in patients with anti-phospholipid syndrome. Their findings provide novel clues for specific targeting therapies in the affected patients.